Acúmulo de minerais em Aechmea blanchetiana (Baker) L.B. Smith (Bromeliaceae), contaminadas com zinco em cultivo in vitro

Com o objetivo de estudar a absorção e translocação de Ca, Co, Fe, K e Zn em Aechmea blanchetiana, plantas foram cultivadas in vitro em meios de cultivo contendo concentrações de Zn (0,0; 0,18; 1,8; 18 e 180 mg Zn L-1). Após 16 semanas de cultivo, os sistemas aéreo e radicular foram separados e determinadas à massa seca para massa de matéria seca e para a análise por ativação com nêutrons (AAN). O procedimento consistiu em irradiar amostras e padrões no reator nuclear de pesquisa IEA-R1 por 16 h para análise por espectrometria de raios gama. O controle dos resultados foi avaliado por meio das análises dos materiais de referência certificados, com desvios padrão relativo de 9,1 % e erros inferiores a 12,9 %. Os resultados das determinações dos elementos mostraram que o Zn alterou absorção e translocação de Ca, Co, Fe, K e Zn. A espécie apresentou alta quantidade de Zn nos sistemas aéreo e radicular indicando, possivelmente, ser bioacumuladora desse elemento.

Effects of pregabalin on behavioral alterations induced by ketamine in rats

Objective: The aim of this study is to investigate the effects of pregabalin on the behavior of rats under the influence of ketamine, an NMDA receptor antagonist that mimics the symptoms of schizophrenia. Methods: Rats were injected with saline or 25 mg/kg ketamine intraperitoneally. After that, behavior modifications were investigated by the evaluation of stereotypy and hyperlocomotion, after treating rats with pregabalin (at doses of 30 mg/kg or 100 mg/kg) or placebo (saline solution). Results: The administration of pregabalin reduced ketamine-induced hyperlocomotion. However, neither doses of pregabalin had a significant effect on ketamine-induced stereotypy. Conclusion: This is the first study to investigate the effects of pregabalin using an animal model of psychosis. Furthermore, our results indicate that behavioral changes induced by ketamine in rats can be reversed with the use of pregabalin, suggesting its potential to treat psychotic symptoms.

Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis

For the last 40 years, schizophrenia has been considered to be the result primarily of a dysfunction in brain dopaminergic pathways. In this review, it is described and discussed findings concerning nitric oxide-mediated neurotransmission in schizophrenia. Studies were searched in PubMed, SciELO, and LILACS using the terms schizophrenia and nitric oxide plasma levels or nitric oxide serum levels, with no time limit. The reference lists of selected articles were also hand-searched for additional articles. From 15 potential reports, 10 were eligible to be included in the review and meta-analysis. These studies included a total of 505 patients with schizophrenia and 339 healthy volunteers. No significant difference was found between patients and healthy controls regarding total nitrite plasma/serum levels (effect size g = 0.285, 95%CI = -0.205 to 0.774, p = 0.254). However, when studies with patients under antipsychotic treatment were examined separately, there was a significant difference between patients and healthy volunteers (effect size g = 0.663, 95%CI = 0.365 to 0.961, p < 0.001), showing that patients under treatment have higher levels of plasma/serum nitric oxide than controls. These results suggest that antipsychotics increase nitric oxide plasma/serum levels and that the nitrergic pathway would be a fertile target for the development of new treatments for patients with schizophrenia.